|
Prosonix World Leader in Ultrasonic Crystallization and Particle Engineering |
 |
 |
 |
|
Written by Graham Ruecroft
|
|
Friday, 19 December 2008 12:23 |
|
Prosonix is the world leader in the commercialization of proprietary pharmaceutical ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions.
 Based in Oxford UK, our team of chemists and engineers combine to give Prosonix a unique multidisciplinary approach to solving our customers complex problems. We leverage our proprietary intellectual property and patented bespoke sonoprocessing equipment to deliver long term and sustainable value.
 Our core markets to date are pharmaceuticals, fine chemicals and minerals processing, where we employ our technology for the “Complete Crystallization Control” of our customer's products, processes and unit operations. A core expertise is the development of new ‘molecule to particle’ methods for manufacture of inhaled medicines.
To complement our market led internal R & D programmes, we are actively engaged in several strategic partnerships with leading academic and technology institutions. These partnerships place us firmly at the cutting edge of the next generation of commercial scale ultrasonic assisted pharmaceutical particle engineering & process intensification solutions.
Partner with Prosonix today |
|
Last Updated on Sunday, 22 March 2009 21:08 |
|
|
Prosonix Attains International Quality Approval |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 26 June 2009 08:02 |
|
 Prosonix (Oxford, UK) is pleased to announce that it has achieved accreditation to the Quality Management standard ISO 9001:2008 following a recent audit of business systems and procedures by independent external auditors SGS (UK) Ltd.
|
|
Last Updated on Friday, 26 June 2009 10:51 |
|
Read more...
|
|
KTP Research Funding For Prosonix and Bath University |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 08 May 2009 17:00 |
 Prosonix will be recruiting a high quality researcher in light of the recent announce -ment that a research grant of £190,500 has been awarded to the Department of Pharmacy and Pharmacology and Prosonix to develop methodology and identify new processing technology for the manufacture of pharmaceutical co-crystals and binary API crystals suitable for use in inhaled and oral medicines.
|
|
Last Updated on Saturday, 09 May 2009 18:30 |
|
Read more...
|
|
|
Prosonix and Aeropharm Announce Agreement |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 19 December 2008 12:35 |
 Prosonix Ltd (Oxford, UK) is delighted to announce a new agreement for the application of its proprietary ultrasonic particle engineering technology in the pharmaceutical industry. This new agreement has been concluded with Aeropharm (Rudolstadt, Germany) and is concerned with the development and manufacture of a new generation of "difficult-to-make" generic products.
|
|
Last Updated on Tuesday, 03 February 2009 22:14 |
|
Read more...
|
|
Pfizer Selects Prosonix Crystallization Technology |
|
|
|
|
Written by Christian Jones
|
|
Friday, 19 December 2008 11:47 |
 Prosonix Ltd (Oxford, UK) is delighted to announce that Pfizer Global Manufacturing will implement Prosonix’ Prosonitron reactor and sonocrystallization process technology at Pfizer’s manufacturing facilities in Ireland.
|
|
Last Updated on Tuesday, 03 February 2009 22:15 |
|
Read more...
|
|
|
Prosonix are world leaders in ultrasonic particle engineering and supply of proprietary sonocrystallization techniques. Our income streams are derived from funded collaborations, technology licensing, and pharma product supply. Prosonix technologies give quantifiable productivity and performance enhancements in the primary and secondary manufacture of Advanced Pharmaceutical Ingredients (APIs), excipients and drug products. 
Prosonitron™, DISCUS™, SAX™ & PRT based process technologies are proprietary “Solution-to-Particle” methods for controlling crystal size, shape and polymorph for APIs and excipients. Technologies offer dose-to-dose uniformity, formulation consistency, stability and 200% performance increase of inhaled APIs compared to micronized. Combination particles of multiple APIs can be manufactured. 
Power ultrasound facilitates controlled and reproducible crystal nucleation which is fundamental in controlling crystallization. Sonocrystallization delivers controlled nucleation and superior control of particle size, morphology, polymorphism, crystallinity and purity, and in doing so helps eliminate the need for troublesome external seeding and micronization for inhaled medicines.
Multipurpose laboratory equipment for sonocrystallization & sonochemistry are now available. These highly effective and flexible research tools facilitate 100ml – 100L operational capability in batch or continuous operation and can be integrated with automated laboratory reactors. The unique designs allow seamless transition and scale up to Prosonitron™ technology for commercial scale operation. 
Prosonix provide cGMP & ATEX sonocrystallization Prosonitron™ ultrasonic process and reactor technology. They are aligned with emergent FDA “QbD” and “Design for Intent” philosophy. Our proprietary systems are of modular design for optimum flexibility and are an easy retro-fit to existing equipment. They are proven across scale in API production and can be seen as sustainable green technology. 
